Effects of Polymorphisms in <i>ABCG2</i> , <i>SLCO1B1</i> , <i>SLC10A1</i> and <i>CYP2C9</i> / <i>19</i> on Plasma Concentrations of Rosuvastatin and Lipid Response in Chinese Patients

Abstract

These findings suggest that the increased plasma concentrations of rosuvastatin in Chinese patients are associated with increased lipid-lowering effects and lower doses of rosuvastatin should be effective in subjects with the ABCG2 421C>A variant.